ArticleFrontiers in neurology2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Open access · goldAbstract read
In one paragraph
Article in Frontiers in neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
6.9field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 81 citations in OpenAlex.
- Phase 1, randomized trials of MEDI1341: cerebrospinal fluid free α-synuclein lowered by >50.Brain communications · 2025Trial
- Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.Nature medicine · 2024Trial
- Reliability and validity of the Roche PD Mobile Application for remote monitoring of early Parkinson's disease.Scientific reports · 2022Trial
- The irony of Parkinson's disease: Converging mechanisms of redox imbalance and ferroptosis.Redox biology · 2026Review
- Immune-mediated excitotoxicity in brain disorders.Nature reviews. Immunology · 2026Review
- Long-Duration Response to Levodopa in the PPMI-Cohort.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- From synaptic development to degeneration: a narrative review of small molecule strategies targeting alpha-synuclein in Parkinson's disease.Metabolic brain disease · 2026Review
- Walking as a Window to the Brain: Redefining Gait in Neurology.Medical sciences (Basel, Switzerland) · 2026Review
- Progress of Immunotherapies in Parkinson's Disease.CNS neuroscience & therapeutics · 2026Review
- Research progress on the α-synuclein-lysosome axis in Parkinson's disease: molecular mechanisms of protein aggregation, autophagy dysfunction, and therapeutic targeting.Frontiers in neuroscience · 2026Review
- Network-Medicine-Guided Drug Repurposing for Alzheimer's Disease: A Multi-Dimensional Systems Pharmacology Approach.International journal of molecular sciences · 2025Article
- Toward Personalized Medicine in Parkinson's Disease: A Scoping Review of Biomarkers, Genetics, and Treatment Stratification.Journal of clinical practice and research · 2025Review
- Recent Advances in Autophagy and Immunotherapy for the Clearance of Aggregated α-Synuclein in Parkinson's Disease.Aging and disease · 2025Review
- The Search for Disease Modification in Parkinson's Disease-A Review of the Literature.Life (Basel, Switzerland) · 2025Review
- Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials.Translational neurodegeneration · 2025Review
- Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.NPJ digital medicine · 2025Article
- Neuroinflammation: Mechanisms, Dual Roles, and Therapeutic Strategies in Neurological Disorders.Current issues in molecular biology · 2025Review
- Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies.NPJ Parkinson's disease · 2025Article
- Prioritizing Parkinson's disease risk genes in genome-wide association loci.NPJ Parkinson's disease · 2025Article
- Drug discovery and development for Parkinson's disease: are preclinical models good enough?Frontiers in aging neuroscience · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 7 institutions in 5 countries.
Gennaro PaganoRoche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Frank G BoessRoche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Kirsten I TaylorRoche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Benedicte RicciRoche Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Brit MollenhauerParacelsus-Elena-Klinik, Kassel, Germany.
Werner PoeweDepartment of Neurology, Innsbruck Medical University, Innsbruck, Austria.
Anne BoulayIdorisa Pharmaceuticals Ltd., Allschwil, Switzerland.
Judith Anzures-CabreraRoche Products Ltd., Welwyn Garden City, United Kingdom.
Annamarie VogtRoche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Maddalena MarchesiRoche Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Anke PostFeetme SAS, Paris, France.
Tania NikolchevaF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Gene G KinneyProthena Biosciences Inc., South San Francisco, CA, United States.
Wagner M ZagoProthena Biosciences Inc., South San Francisco, CA, United States.
Daniel K NessProthena Biosciences Inc., South San Francisco, CA, United States.
Hanno SvobodaRoche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Markus BritschgiRoche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Susanne OstrowitzkiF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Tanya SimuniDepartment of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Kenneth MarekInstitute for Neurodegenerative Disorders, New Haven, CT, United States.
Martin KollerProthena Biosciences Inc., South San Francisco, CA, United States.
Jeff SevignyPrevail Therapeutics, New York, NY, United States.
Rachelle DoodyF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Paulo FontouraF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Daniel UmbrichtRoche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Azad BonniRoche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
PASADENA Investigators
Prasinezumab Study Group
Roche (Switzerland) · CHProthena (United States) · USInnsbruck Medical University · ATInstitute for Neurodegenerative Disorders · USNorthwestern University · USParacelsus Elena Klinik Kassel · DERoche (United Kingdom) · GB
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
alpha-synuclein (α-syn)disease modification treatmentsdisease progressionMDS-UPDRS = Movement Disorder Society—Unified Parkinson's Disease Rating Scalemonoclonal antibodiesParkinson's diseasePhase II clinical trialprasinezumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.